Effect of aggressive therapy on laryngeal symptoms and voice characteristics in patients with gastroesophageal reflux.
Gastroesophageal reflux (GER) is associated with a variety of laryngopharyngeal signs and symptoms. Injury of the laryngopharynx as a result of GER can be refractory to conventional antireflux therapy. This prospective study was undertaken to evaluate the prevalence of laryngopharyngeal signs and symptoms in patients with documented GER and to assess the response to a high-dose combination antireflux therapy consisting of cisapride and pantoprazole. Twenty-two patients with symptoms of GER were enrolled. After baseline evaluation using a history questionnaire for symptoms, laryngeal endoscopy and vocal acoustic analysis, patients were started on treatment consisting of pantoprazole 40 mg b.d. and cisapride 20 mg twice daily. Repeat history and otolaryngologic evaluation was performed at 4 weeks. Laryngopharyngeal symptoms were frequent in most patients, with throat clearing and globus being the most prevalent symptoms followed by vocal fatigue and excess mucus production. Almost 90% of the patients had abnormal endoscopic laryngeal findings but the acoustic parameters did not show any abnormal results except for mild elevation in the shimmer. After treatment, all symptoms and endoscopic abnormalities improved significantly except for intermittent dysphonia and laryngeal mucosal redness. Acoustic abnormalities did not change significantly following therapy. Laryngeal symptoms and voice abnormalities are highly prevalent in patients with GER. Combination antireflux therapy with a proton pump inhibitor and a prokinetic agent results in rapid symptomatic and endoscopic response in the majority of patients.
Hamdan
A L
AL
Department of Otolaryngology-Head and Neck Surgery, American University of Beirut Medical Center, Lebanon.
Sharara
A I
AI
Younes
A
A
Fuleihan
N
N
D053799:2-Pyridinylmethylsulfinylbenzimidazoles; D000897:Anti-Ulcer Agents / Q000627:therapeutic use*; D001562:Benzimidazoles / Q000627:therapeutic use*; D020117:Cisapride / Q000627:therapeutic use*; D005764:Gastroesophageal Reflux / Q000150:complications* / Q000188:drug therapy*; D006801:Humans; D007827:Laryngitis / Q000175:diagnosis / Q000209:etiology*; D007828:Laryngoscopy / Q000379:methods; D009853:Omeprazole / Q000031:analogs & derivatives; D000077402:Pantoprazole; D015995:Prevalence; D011446:Prospective Studies; D013454:Sulfoxides / Q000627:therapeutic use*; D011795:Surveys and Questionnaires; D014832:Voice Disorders / Q000175:diagnosis / Q000209:etiology; D014833:Voice Quality
D053799:2-Pyridinylmethylsulfinylbenzimidazoles; D000897:Anti-Ulcer Agents; D001562:Benzimidazoles; D013454:Sulfoxides; D000077402:Pantoprazole; D009853:Omeprazole; D020117:Cisapride